Results 41 to 50 of about 89 (85)
Deciphering Freezing of Gait: What Neuropathology Reveals About an Episodic Phenomenon
Freezing of gait (FoG) occurs across Parkinson's disease, multiple neurodegenerative conditions and non‐neurodegenerative disorders. This review synthesizes the structural, neurochemical and proteinopathic substrates underlying FoG, showing how cumulative damage to distributed locomotor circuits—compounded by overlapping pathologies—progressively ...
Gabor G. Kovacs
wiley +1 more source
2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C
ABSTRACT In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal ...
Tarekegn Hiwot +33 more
wiley +1 more source
IntroductionLate infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare neurodegenerative paediatric disorder in the neuronal ceroid lipofuscinoses (NCL) family of lysosomal storage disorders1 CLN2 disease is caused by mutations in TPP1, which result in deficiencies of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), leading to ...
Mazurkiewicz-Beldziska, Maria +10 more
openaire +3 more sources
ABSTRACT Neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a lysosomal storage disorder, causes early childhood psychomotor regression, vision loss, seizures, and rapid progressive gray matter loss. However, the link between neurodegenerative processes induced by lysosomal pathophysiology and the clinical phenotype remains unclear.
Marvin Petersen +12 more
wiley +1 more source
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld +5 more
wiley +1 more source
Neuronal ceroid lipofuscinoses are one of the most common neurometabolic disorders in children. Enhanced diagnostic and therapeutic possibilities, primarily for ceroid lipofuscinosis type 2, presents a challenge for timely diagnosis, which is mostly off ered in large diagnostic centres.
Fumić, Ksenija, Bilandžija Kuš, Iva
openaire +1 more source
Neuronal ceroid lipofuscinoses (NCLs) are a heterogeneous group of lysosomal storage disorders. NCLs include the rare autosomal recessive neurodegenerative disorder neuronal ceroid lipofuscinosis type 2 (CLN2) disease, caused by mutations in the tripeptidyl peptidase 1 (TPP1)/CLN2 gene and the resulting TPP1 enzyme deficiency.
Fietz, Michael +17 more
openaire +4 more sources
Early diagnosis of neuronal ceroid lipofuscinosis type 2 – a myth or reality?
Neuronska ceroidna lipofuscinoza-tip 2 (CLN2) najčešća je dječja progresivna neurodegenerativna bolest. Glavna obilježja bolesti CLN2 su usporen razvoj govora koji prethodi epileptičkim napadajima, motoričkim poremećajima, progresivnom propadanju vida i kognitivnih funkcija te smrti u dobi rane adolescencije.
openaire +3 more sources
New Drug: Cerliponase alfa for neuronal ceroid lipofuscinosis type 2 disease [PDF]
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Review of Pharmacoeconomics & Outcomes Research, 2023
Cerliponase alfa is an orphan drug approved for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).Our goal was to assess the cost-effectiveness of cerliponase alfa in patients with CLN2 in the socioeconomic context of the Republic of Serbia in contrast to symptomatic therapy.For this study, a forty-year horizon and the ...
Medo Gutić +4 more
openaire +2 more sources
Cerliponase alfa is an orphan drug approved for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).Our goal was to assess the cost-effectiveness of cerliponase alfa in patients with CLN2 in the socioeconomic context of the Republic of Serbia in contrast to symptomatic therapy.For this study, a forty-year horizon and the ...
Medo Gutić +4 more
openaire +2 more sources

